Learning & research

Invasive right heart catheterization (RHC) remains the reference standard for diagnosing pulmonary hypertension (PH), but there is a pressing need for non-invasive techniques to assess pulmonary hemodynamics. This study evaluates 4D-flow MRI-derived wall shear stress (WSS) for PH detection using the updated 2022 hemodynamic criteria, and the prediction of right ventriculo-pulmonary arterial (RV-PA) uncoupling to assess disease severity. 

Risk stratification is essential in pulmonary arterial hypertension (PAH), yet the prognostic utility of the albumin-bilirubin (ALBI) score as a marker of hepatic dysfunction remains underexplored. In this single-center study, we evaluated the clinical, neurohumoral, echocardiographic and hemodynamic correlates and prognostic value of the ALBI score, and to assess whether this score offers an incremental benefit over the Registry to EValuate Early And Long-term pulmonary arterial hypertension disease management (REVEAL) 2.0 risk score in patients with PAH.

Chronic thromboembolic pulmonary hypertension (CTEPH) can be treated by mechanical therapy with pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA). Haemodynamic treatment goal is ill-defined. We explored post-procedure mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), and its relationship with 5-Year survival and exercise capacity Using 6-min Walk Distance (6MWD).

Pulmonary hypertension (PH) is a fatal sequela in sickle cell disease (SCD) patients and occurs with greater prevalence compared to the general population. Macrophages (Mϕ) are one of the first immune cells to be recruited to the lungs in mouse models of PH, including SCD-PH, and a key cell type that contribute toward disease progression.

Selexipag is an oral prostacyclin receptor agonist approved for pulmonary arterial hypertension (PAH). This single-center, retrospective study described oral selexipag dosing patterns and persistence, overall and stratified by history of methamphetamine (meth) use, at an expert center in California, USA, using a multidisciplinary, nurse-directed protocol entailing frequent follow-up and individualized side effect management.

The role of antithrombotic therapy in pulmonary hypertension (PH) remains uncertain, with conflicting adult data and limited pediatric evidence. This study aimed to describe real-world antithrombotic use in pediatric PH utilizing Pediatric Pulmonary Hypertension Network (PPHNet) registry data and a survey of PPHNet centers. 

Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare cause of acute cor pulmonale, typically associated with advanced solid tumors; its occurrence as the initial presentation of multiple myeloma (MM) has not been described. 

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease with substantial physiological and psychosocial burden. Effective patient education is essential for self-management and improved outcomes, yet access to reliable information remains limited by brief clinic visits and variable-quality external resources.

Pulmonary arterial hypertension (PAH) is a progressive and lethal disorder with limited therapeutic options. β-sitosterol, a plant compound, has shown potential in managing PAH, but its protective mechanisms remain unclear. We evaluated the protective effects of β-sitosterol against monocrotaline (MCT)-induced PAH in rats and explored the underlying mechanisms.

We retrospectively studied a cohort of 98 patients who underwent electrocardiography (ECG), echocardiography, and right heart catheterization within 48 h from 2021 to 2023.